US2023304068A1PendingUtilityA1

Modulation of gene expression in a human bioreactor

64
Assignee: MAXWELL BIOSCIENCES INCPriority: Jan 25, 2019Filed: May 31, 2023Published: Sep 28, 2023
Est. expiryJan 25, 2039(~12.5 yrs left)· nominal 20-yr term from priority
A61K 31/05C12Q 1/68G01N 33/5091G01N 33/5094A61K 35/16C12Q 2560/00A61K 38/2292A61K 31/455A61K 38/44A61K 9/0019A61K 9/0053A61K 35/00
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method is provided for treating a recipient with a biological product obtained from at least one donor that may be the same as, or different from, the recipient. The method includes identifying a targeted level of gene expression of a first gene in a biological product to be transferred from at least one donor to a recipient; treating the at least one donor to achieve the targeted level of gene expression of the first gene in the biological product; and transferring the biological product from the at least one donor to the recipient.

Claims

exact text as granted — not AI-modified
101 . A method for treating a recipient, comprising:
 obtaining portions of a biological product from each of a plurality of donors, wherein each portion of the biological product is characterized by a level of a first targeted gene expression;   determining a desired level of the first targeted gene expression in a derived product to be derived from the obtained portions of the biological product;   forming the derived product by creating a mixture of the obtained portions of the biological product having the desired level of the first targeted gene expression; and
 administering the derived product to the recipient.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.